These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28890480)

  • 41. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension.
    Benza RL; Gomberg-Maitland M; Demarco T; Frost AE; Torbicki A; Langleben D; Pulido T; Correa-Jaque P; Passineau MJ; Wiener HW; Tamari M; Hirota T; Kubo M; Tiwari HK
    Am J Respir Crit Care Med; 2015 Dec; 192(11):1345-54. PubMed ID: 26252367
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prostanoid therapy for pulmonary arterial hypertension.
    Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Idiopathic pulmonary arterial hypertension.
    Souza R; Jardim C; Humbert M
    Semin Respir Crit Care Med; 2013 Oct; 34(5):560-7. PubMed ID: 24037625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Response to bosentan in children with pulmonary hypertension.
    Maiya S; Hislop AA; Flynn Y; Haworth SG
    Heart; 2006 May; 92(5):664-70. PubMed ID: 16216850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM; Channick RN
    Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful up-front combination therapy in a patient with idiopathic pulmonary hypertension and patent foramen ovale: an alternative to epoprostenol therapy?
    Pitsiou GG; Chavouzis N; Nakou C; Boutou AK; Argyropoulou P; Stanopoulos I
    J Heart Lung Transplant; 2009 Jun; 28(6):651-3. PubMed ID: 19481029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostacyclin therapy for pulmonary arterial hypertension: new directions.
    Gomberg-Maitland M; Preston IR
    Semin Respir Crit Care Med; 2005 Aug; 26(4):394-401. PubMed ID: 16121316
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Endothelin-1 across the lung circulation in patients with pulmonary arterial hypertension and influence of epoprostenol infusion.
    Selimovic N; Andersson B; Bergh CH; Sakiniene E; Carlsten H; Rundqvist B
    J Heart Lung Transplant; 2009 Aug; 28(8):808-14. PubMed ID: 19632577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
    Barst R
    Int J Clin Pract Suppl; 2010 Nov; (168):23-32. PubMed ID: 20939843
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
    Lammi MR; Mathai SC; Saketkoo LA; Domsic RT; Bojanowski C; Furst DE; Steen VD;
    Arthritis Rheumatol; 2016 Mar; 68(3):740-8. PubMed ID: 26479414
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.
    Bergot E; Sitbon O; Cottin V; Prévot G; Canuet M; Bourdin A; de Groote P; Rottat L; Gressin V; Jaïs X; Humbert M; Simonneau G
    Int J Cardiol; 2014 Apr; 172(3):561-7. PubMed ID: 24529947
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.
    Clements PJ; Tan M; McLaughlin VV; Oudiz RJ; Tapson VF; Channick RN; Rubin LJ; Langer A;
    Ann Rheum Dis; 2012 Feb; 71(2):249-52. PubMed ID: 21998119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single-Center Experience Using Selexipag in a Pediatric Population.
    Gallotti R; Drogalis-Kim DE; Satou G; Alejos J
    Pediatr Cardiol; 2017 Oct; 38(7):1405-1409. PubMed ID: 28702718
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.
    Burger CD
    Ann Am Thorac Soc; 2015 Jun; 12(6):959. PubMed ID: 26075561
    [No Abstract]   [Full Text] [Related]  

  • 58. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol.
    Badesch DB; McGoon MD; Barst RJ; Tapson VF; Rubin LJ; Wigley FM; Kral KM; Raphiou IH; Crater GD
    J Rheumatol; 2009 Oct; 36(10):2244-9. PubMed ID: 19723905
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adult congenital heart disease and pulmonary arterial hypertension: the Texas Adult Congenital Heart Program experience.
    Franklin WJ; Parekh DR; Safdar Z
    Postgrad Med; 2011 Nov; 123(6):32-45. PubMed ID: 22104452
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
    Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
    Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.